Your browser doesn't support javascript.
loading
Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth.
Yakes, F Michael; Chen, Jason; Tan, Jenny; Yamaguchi, Kyoko; Shi, Yongchang; Yu, Peiwen; Qian, Fawn; Chu, Felix; Bentzien, Frauke; Cancilla, Belinda; Orf, Jessica; You, Andrew; Laird, A Douglas; Engst, Stefan; Lee, Lillian; Lesch, Justin; Chou, Yu-Chien; Joly, Alison H.
Affiliation
  • Yakes FM; Exelixis, Inc., 210 East Grand Ave, South San Francisco, CA 94083, USA. myakes@exelixis.com
Mol Cancer Ther ; 10(12): 2298-308, 2011 Dec.
Article in En | MEDLINE | ID: mdl-21926191
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pyridines / Cell Growth Processes / Anilides / Neoplasm Metastasis / Neoplasms / Neovascularization, Pathologic Type of study: Prognostic_studies Limits: Animals / Female / Humans Language: En Journal: Mol Cancer Ther Journal subject: ANTINEOPLASICOS Year: 2011 Document type: Article Affiliation country:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pyridines / Cell Growth Processes / Anilides / Neoplasm Metastasis / Neoplasms / Neovascularization, Pathologic Type of study: Prognostic_studies Limits: Animals / Female / Humans Language: En Journal: Mol Cancer Ther Journal subject: ANTINEOPLASICOS Year: 2011 Document type: Article Affiliation country: